• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    US Stocks Turn Lower; S&P 500 Down 1%

    3/9/23 2:25:07 PM ET
    $AKBA
    $GNE
    $HLLY
    $JD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Power Generation
    Utilities
    Get the next $AKBA alert in real time by email

    U.S. stocks turned lower toward the end of trading, with the Dow Jones dropping around 300 points on Thursday.

    The Dow traded down 0.88% to 32,510.83 while the NASDAQ fell 1.34% to 11,421.06. The S&P 500 also fell, dropping, 1.08% to 3,948.74.

    Check This Out: $5M Bet On FIGS? Check Out These 3 Stocks Insiders Are Buying

     

    Leading and Lagging Sectors

    • Utilities shares rose by 1.1% on Thursday. Meanwhile, top gainers in the sector included ReNew Energy Global Plc (NASDAQ:RNW), up 4%, and Genie Energy Ltd. (NYSE:GNE), up 4%.
    • In trading on Thursday, financial shares dipped by 2.5%.

     

    Top Headline

    JD.com, Inc (NASDAQ:JD) reported better-than-expected Q4 results.

    JD.com reported fourth-quarter FY22 revenue growth of 7.1% year-on-year to $42.84 billion, beating the consensus of $42.73 billion. Non-GAAP net income per ADS of $0.70 beat the consensus of $0.50.

     

    Equities Trading UP

    • Ocean Biomedical, Inc. (NASDAQ:OCEA) shares shot up 75% to $8.19 after the company shared detailed research data on anti-tumor pathway discoveries and their potential for treatment of non-small cell lung cancer, metastatic melanoma, and glioblastoma by Scientific Co-founder, Dr. Jack A. Elias, MD.
    • Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) got a boost, shooting 32% to $0.6979. Neoleukin Therapeutics engaged SVB Securities to assist in reviewing strategic alternatives. The company also approved a further corporate restructuring to preserve cash, including reducing its workforce by approximately 70%.
    • Holley Inc. (NYSE:HLLY) shares were also up, gaining 53% to $3.03 after the company reported Q4 financial results.

     

    Equities Trading DOWN

    • Akebia Therapeutics, Inc. (NASDAQ:AKBA) shares tumbled 23% to $0.7960 after the company reported Q4 financial results.
    • Shares of SVB Financial Group (NASDAQ:SIVB) were down 47% to $141.55 after the parent of Silicon Valley Bank announced proposed offerings of common stock and convertible preferred stock.
    • InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) was down, falling 45% to $1.1609 after the company announced topline data from its INSPIRE 2.0 study in acute spinal cord injury, in which the primary endpoint was not met.

    Also Check This Out: Crypto Market Cap Falls Below $1 Trillion; ImmutableX, Synthetix Among Top Losers

     

    Commodities

    In commodity news, oil traded up 0.2% to $76.80 while gold traded up 0.8% at $1,832.90.

    Silver traded up 0.2% to $20.185 on Thursday while copper rose 0.1% to $4.0300.

     

    Euro zone

    European shares closed lower today. The eurozone’s STOXX 600 fell 0.22%, London’s FTSE 100 fell 0.63% while Spain’s IBEX 35 Index fell 0.45%. The German DAX gained 0.01% French CAC 40 fell 0.12% and Italy’s FTSE MIB Index fell 0.72%.

    Payroll employment in the French private sector rose by 0.2% to 21.03 million during the fourth quarter, compared to a 87.6 thousand growth in the prior three-month period.

     

    Asia Pacific Markets

    Asian markets closed mostly lower on Thursday, with Japan’s Nikkei 225 gaining 0.63%, Hong Kong’s Hang Seng Index dropping 0.63% and China’s Shanghai Composite Index falling 0.22%. India’s S&P BSE Sensex dropped 0.9%.

    Chinese annual inflation rate eased to 1.0% in February from 2.1% in the previous month, while producer prices declined 1.4% from a year ago in February. The Japanese economy grew by an annualized rate of 0.1% in the fourth quarter versus the preliminary figure of a 0.6% growth.

     

    Economics

    • US initial jobless claims climbed by 21,000 from the prior week to 211,000 in the week ending March 4, higher than market estimates of 195,000.
    • US natural-gas supplies dropped 84 billion cubic feet last week, the EIA said.

    Now Read This: Top 5 Consumer Staples Stocks That Could Lead To Your Biggest Gains In March

     

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 105,524,390 cases with around 1,148,090 deaths. India confirmed a total of at least 44,688,690 cases and 530,770 deaths, while France reported over 39,639,110 COVID-19 cases with 165,070 deaths. In total, there were at least 681,090,770 cases of COVID-19 worldwide with more than 6,808,370 deaths.

     

    Get the next $AKBA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKBA
    $GNE
    $HLLY
    $JD

    CompanyDatePrice TargetRatingAnalyst
    JD.com Inc.
    $JD
    12/9/2025$32.00Buy → Neutral
    Arete
    JD.com Inc.
    $JD
    11/10/2025$28.00Equal-Weight → Underweight
    Morgan Stanley
    ReNew Energy Global plc
    $RNW
    10/29/2025$8.15Outperform → Neutral
    Mizuho
    JD.com Inc.
    $JD
    9/26/2025$41.00Sell → Buy
    Arete
    JD.com Inc.
    $JD
    8/11/2025$42.00Buy
    Citigroup
    Holley Inc.
    $HLLY
    8/8/2025$4.00Hold → Buy
    The Benchmark Company
    JD.com Inc.
    $JD
    6/24/2025$45.00Buy → Neutral
    Arete
    Akebia Therapeutics Inc.
    $AKBA
    6/4/2025$8.00Buy
    H.C. Wainwright
    More analyst ratings

    $AKBA
    $GNE
    $HLLY
    $JD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

    CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that members of its executive team will participate in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12 at 9:30 AM EST. A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference. The Emerging Outlook: Biotech Summit hosted by Guggenheim Securities, LLC, will take place February 11-12, in New York City. About Akebia Therapeutics Akebia Therap

    2/4/26 8:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 132,675 shares of Akebia's common stock on January 30, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.41 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of

    2/2/26 4:05:00 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Holley Performance Brands Redefines a Legacy With Launch of "American Performance" Vertical

    BOWLING GREEN, Ky., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Holley Performance Brands (NYSE:HLLY), a leader in automotive aftermarket performance solutions, today announced the renaming of its flagship consumer vertical from "Domestic Muscle" to "American Performance." The evolution reflects a generational shift in enthusiast behavior, supported by new internal research and market observations showing sustained growth across 1980s–2000s American vehicle platforms, including trucks, SUVs and muscle cars. For years, the domestic muscle naming convention was often viewed as a legacy segment. Iconic, but focused only on older 60s and 70s muscle cars and plateauing. Holley's analysis of search behav

    1/22/26 9:00:00 AM ET
    $HLLY
    Auto Parts:O.E.M.
    Consumer Discretionary

    $AKBA
    $GNE
    $HLLY
    $JD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Chief Accounting Officer Malabre Richard C sold $68,838 worth of shares (49,524 units at $1.39), decreasing direct ownership by 14% to 299,390 units (SEC Form 4)

    4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

    2/4/26 4:15:29 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Grund Nicholas sold $117,912 worth of shares (84,829 units at $1.39), decreasing direct ownership by 13% to 561,750 units (SEC Form 4)

    4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

    2/4/26 4:13:46 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Medical Officer Burke Steven Keith sold $94,045 worth of shares (67,658 units at $1.39), decreasing direct ownership by 7% to 948,432 units (SEC Form 4)

    4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

    2/4/26 4:13:17 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    $GNE
    $HLLY
    $JD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Exec. Chairman of the Board Rubel Matthew E bought $49,131 worth of shares (14,493 units at $3.39), increasing direct ownership by 9% to 169,979 units (SEC Form 4)

    4 - Holley Inc. (0001822928) (Issuer)

    6/14/24 5:24:29 PM ET
    $HLLY
    Auto Parts:O.E.M.
    Consumer Discretionary

    Clempson Graham bought $420,101 worth of shares (100,000 units at $4.20) (SEC Form 4)

    4 - Holley Inc. (0001822928) (Issuer)

    3/18/24 4:07:20 PM ET
    $HLLY
    Auto Parts:O.E.M.
    Consumer Discretionary

    Foose Brice closing all direct ownership in the company (SEC Form 4)

    4 - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Issuer)

    2/7/24 1:31:40 PM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKBA
    $GNE
    $HLLY
    $JD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JD.com downgraded by Arete with a new price target

    Arete downgraded JD.com from Buy to Neutral and set a new price target of $32.00

    12/9/25 8:38:49 AM ET
    $JD
    Other Specialty Stores
    Consumer Discretionary

    JD.com downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded JD.com from Equal-Weight to Underweight and set a new price target of $28.00

    11/10/25 8:43:51 AM ET
    $JD
    Other Specialty Stores
    Consumer Discretionary

    ReNew downgraded by Mizuho with a new price target

    Mizuho downgraded ReNew from Outperform to Neutral and set a new price target of $8.15

    10/29/25 7:53:21 AM ET
    $RNW
    Electric Utilities: Central
    Utilities

    $AKBA
    $GNE
    $HLLY
    $JD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

    Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

    3/28/24 10:46:38 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    $GNE
    $HLLY
    $JD
    SEC Filings

    View All

    Genie Energy Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Genie Energy Ltd. (0001528356) (Filer)

    2/5/26 4:40:56 PM ET
    $GNE
    Power Generation
    Utilities

    Akebia Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Leadership Update, Financial Statements and Exhibits

    8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

    1/30/26 8:34:33 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by ReNew Energy Global plc

    SCHEDULE 13G/A - ReNew Energy Global plc (0001848763) (Subject)

    1/29/26 11:18:13 AM ET
    $RNW
    Electric Utilities: Central
    Utilities

    $AKBA
    $GNE
    $HLLY
    $JD
    Leadership Updates

    Live Leadership Updates

    View All

    Holley Performance Brands Appoints Del Bohlman as Vice President, Safety & Racing Division

    BOWLING GREEN, Ky., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Holley Performance Brands (NYSE:HLLY), a leader in automotive aftermarket performance solutions, today announced the appointment of Del Bohlman as vice president of its Safety & Racing Division, effective Jan. 1, 2026. Bohlman succeeds Brian Appelgate, who is retiring after a distinguished four-decade career in the performance automotive industry. Bohlman brings more than 20 years of global leadership experience in the powersports and performance sectors, most recently as CEO of Dealer Rocket LLC and previously in senior roles at Bombardier Recreational Products (BRP). At BRP, Bohlman led global services, parts, accessories and garment

    1/20/26 8:30:00 AM ET
    $HLLY
    Auto Parts:O.E.M.
    Consumer Discretionary

    Holley Performance Brands Expands Sales Organization, Appoints Chet Baker Senior Vice President of Sales

    Baker is a proven leader who will help strengthen the company's customer focus in key vertical groupings Holley Performance Brands (NYSE:HLLY), a leader in automotive aftermarket performance solutions, today announced Chet Baker has joined the organization as Senior Vice President of Sales. Baker is among several new sales leaders to recently join the organization as the company strengthens its sales team to engage enthusiasts more directly across the company's consumer vertical groupings: Domestic Muscle, Modern Truck & Off-Road, Euro & Import, and Safety & Racing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240408486488/e

    4/10/24 8:30:00 AM ET
    $HLLY
    Auto Parts:O.E.M.
    Consumer Discretionary

    Holley Performance Brands Appoints Two New Vice Presidents Focused on Accelerating Strategic Growth Across Key Performance Aftermarket Verticals

    Automotive industry experts Charlie Taylor and Will Robbins join Holley Performance Brands to lead digital strategy and consumer product strategy, respectively Holley Performance Brands (NYSE:HLLY), a leader in automotive aftermarket performance solutions, today announced the addition of two new senior leaders who will focus on enhancing the customer experience across Holley's portfolio of iconic brands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240325444873/en/Will Robbins (Photo: Business Wire) Charlie Taylor and Will Robbins, who collectively represent nearly 50 years of automotive industry experience, have joined the

    3/26/24 8:30:00 AM ET
    $HLLY
    Auto Parts:O.E.M.
    Consumer Discretionary

    $AKBA
    $GNE
    $HLLY
    $JD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ReNew Energy Global plc

    SC 13D/A - ReNew Energy Global plc (0001848763) (Subject)

    12/10/24 7:57:27 PM ET
    $RNW
    Electric Utilities: Central
    Utilities

    Amendment: SEC Form SC 13D/A filed by ReNew Energy Global plc

    SC 13D/A - ReNew Energy Global plc (0001848763) (Subject)

    12/10/24 7:53:40 PM ET
    $RNW
    Electric Utilities: Central
    Utilities

    Amendment: SEC Form SC 13D/A filed by ReNew Energy Global plc

    SC 13D/A - ReNew Energy Global plc (0001848763) (Subject)

    12/10/24 7:32:48 PM ET
    $RNW
    Electric Utilities: Central
    Utilities

    $AKBA
    $GNE
    $HLLY
    $JD
    Financials

    Live finance-specific insights

    View All

    Q32 Bio Sells Complement Inhibitor ADX-097

    -- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million including the $12 million in upfront and near-term payments upon achievement of certain development, regulatory and commercial milestones and eligible for tiered royalties up to a mid-teen percent of annual net sales --  -- Q32 Bio retains wholly owned tissue-targeted complement inhibitor platform, including ADX-096 and other remaining early-stage assets; continuing to evaluate strategic options for these

    12/1/25 7:00:00 AM ET
    $AKBA
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Announces Establishment of Rare Kidney Disease Pipeline

    Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2 trial of Praliciguat, an sGC stimulator, initiated in focal segmental glomerulosclerosis (FSGS) Both trials planned to start treating subjects in 2026 CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the establishment of its rare kidney disease pipeline. The pipeline is comprised of two core product candidates: A

    12/1/25 7:00:00 AM ET
    $AKBA
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JD.com Announces Third Quarter 2025 Results

    BEIJING, Nov. 13, 2025 (GLOBE NEWSWIRE) -- JD.com, Inc. (NASDAQ: JD and HKEX: 9618 (HKD counter) and 89618 (RMB counter), the "Company" or "JD.com"), a leading supply chain-based technology and service provider, today announced its unaudited financial results for the three months ended September 30, 2025. Third Quarter 2025 Highlights Net revenues were RMB299.1 billion (US$142.0 billion) for the third quarter of 2025, an increase of 14.9% from the third quarter of 2024.Net income attributable to the Company's ordinary shareholders was RMB5.3 billion (US$0.7 billion) for the third quarter of 2025, compared to RMB11.7 billion for the third quarter of 2024. Non-GAAP2 net income attributable

    11/13/25 4:30:00 AM ET
    $JD
    Other Specialty Stores
    Consumer Discretionary